Clinical trial · Observational
Portal Vein Stenting for Malignant Obstruction: Feasibility, Safety, and Clinical Outcomes
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Introduction: Pre-hepatic portal hypertension of malignant origin can lead to severe complications such as refractory ascites or gastrointestinal bleeding, significantly impairing patients' quality of life. Available therapeutic options are mainly symptomatic and do not address the venous obstruction. Portal vein stenting represents a minimally invasive alternative, which remains poorly studied in this setting. The aim of our study was to evaluate portal stent patency, as well as clinical efficacy and safety, in patients with symptomatic malignant stenosis or occlusion of the portal system. Methods: The team conducted a retrospective cohort study including 63 consecutive patients treated between April 2004 and March 2024 at CHU l'Archet and CAL Nice for symptomatic malignant stenosis or occlusion of the portal system. All patients underwent percutaneous transhepatic portal vein stenting with uncovered self-expandable metallic stents. The primary endpoint was stent patency, defined as the interval between implantation and the occurrence of an occlusion confirmed by imaging or end of follow-up. Secondary endpoints included technical success, clinical success (improvement of portal hypertension signs), and the occurrence of adverse events, graded according to the 2017 SIR classification.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Biliary Tract Neoplasms | — | UNRESOLVED | — |
| Pancreatic Neoplasm | Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Portal Hypertension | — | UNRESOLVED | — |
| Portal Vein Thrombosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Transhepatic portal vein stent implantation | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with malignant portal vein stenosis/occlusion treated by stent
- interventionNames
- Device: Transhepatic portal vein stent implantation
Primary outcomes (1)
- measure
- Portal vein stent patency.
- timeFrame
- From stent placement until death or loss to follow-up to 110 months.
- description
- Stent patency was assessed using cross-sectional imaging and/or Doppler ultrasound.
Secondary outcomes (3)
- measure
- Clinical efficacy (physiological parameter) of portal vein stenting
- timeFrame
- From stent placement until death or loss to follow-up to 110 months.
- description
- Assessment was performed retrospectively using medical records, imaging studies, and follow-up endoscopy when available.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years. * Presence of symptoms related to portal hypertension (e.g., refractory ascites, gastrointestinal bleeding). * Imaging evidence of stenosis or obstruction of the portal venous system (main portal vein, superior and/or inferior mesenteric vein, spleno-mesenteric confluence, and/or splenic vein). Exclusion Criteria: * Obstruction or stenosis secondary to a malignant/neoplastic process.
References
Publications (0)
Data not yet available